Lucinactant

	WikiDoc Resources for Lucinactant
Articles
Most recent articles on Lucinactant Most cited articles on Lucinactant Review articles on Lucinactant Articles on Lucinactant in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lucinactant Images of Lucinactant Photos of Lucinactant Podcasts & MP3s on Lucinactant Videos on Lucinactant
Evidence Based Medicine
Cochrane Collaboration on Lucinactant Bandolier on Lucinactant TRIP on Lucinactant
Clinical Trials
Ongoing Trials on Lucinactant at Clinical Trials.gov Trial results on Lucinactant Clinical Trials on Lucinactant at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lucinactant NICE Guidance on Lucinactant NHS PRODIGY Guidance FDA on Lucinactant CDC on Lucinactant
Books
Books on Lucinactant
News
Lucinactant in the news Be alerted to news on Lucinactant News trends on Lucinactant
Commentary
Blogs on Lucinactant
Definitions
Definitions of Lucinactant
Patient Resources / Community
Patient resources on Lucinactant Discussion groups on Lucinactant Patient Handouts on Lucinactant Directions to Hospitals Treating Lucinactant Risk calculators and risk factors for Lucinactant
Healthcare Provider Resources
Symptoms of Lucinactant Causes & Risk Factors for Lucinactant Diagnostic studies for Lucinactant Treatment of Lucinactant
Continuing Medical Education (CME)
CME Programs on Lucinactant
International
Lucinactant en Espanol Lucinactant en Francais
Business
Lucinactant in the Marketplace Patents on Lucinactant
Experimental / Informatics
List of terms related to Lucinactant

Lucinactant
Combination of
[[{{{component5}}}]]	? Class
Clinical data
Trade names	Surfaxin
ATC code	R07AA30 (WHO) ;
Identifiers
CAS Number	825600-90-6;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Lucinactant (trade name Surfaxin) is a liquid medication used to treat infant respiratory distress syndrome.^[1] It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012.^[2]

Medical uses

Lucinactant is indicated to improve lung function and reduce duration and risk of mechanical ventilation in children. It can be used up to two years of age and is specified for children who are diagnosed with acute respiratory failure following exposure to a pathogen such as RSV or influenza, including H1N1.^[3]^[4]^[5] Lucinactant is also used to treat meconium aspiration syndrome.^[5]^[6]

Physical and chemical properties

Lucinactant contains the peptide sinapultide (KL4 acetate), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (as the sodium salt), and palmitic acid.

History

The scientific groundwork for lucinactant was laid in the laboratory of Charles Cochrane at The Scripps Research Institute in the 1990s.^[7] The drug was then developed by Discovery Laboratories of Warrington, PA. The path through the approval process was unusually long, reflecting in part challenges in the manufacturing process that needed to be addressed before approval was granted.^[8]

Legal status

Lucinactant is listed as an Orphan Drug Product by the US Food and Drug Administration for several conditions:^[9]^[10]

07-30-1996 Treatment of meconium aspiration syndrome in newborn infants
07-17-1995 Treatment of acute respiratory distress syndrome in adults.
05-23-2006 Prevention of bronchopulmonary dysplasia in premature infants
10-21-2005 Treatment of bronchopulmonary dysplasia in premature infants.
10-18-1995 Treatment of respiratory distress syndrome in premature infants.

Clinical trials in Latin America were criticized for protocol based in potentially unethical principles.^[11] A placebo was used and considered ethical by design since infants born in Latin America usually do not have access to life saving treatment. The intent of Discovery Labs was always to market Surfaxin in the United States, implying burdens on the Latin American children that outweighed the benefits.

References

↑ [1]^{[dead link]}
↑ "FDA approves Surfaxin to prevent breathing disorder in premature infants". Fda.gov. 2012-03-06. Retrieved 2012-10-20.
↑ http://money.cnn.com/news/newsfeeds/articles/globenewswire/182115.htm. Missing or empty |title= (help) ^{[dead link]}
↑ PMID 10508806 (PMID 10508806)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
↑ ^5.0 ^5.1 PMID 15833063 (PMID 15833063)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
↑ PMID 12042546 (PMID 12042546)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
↑ "Scripps Research Discoveries Lead to Newly Approved Drug for Infant Respiratory Distress Syndrome". Scripps.edu. 2012-03-06. Retrieved 2012-10-20.
↑ "Pharmaceutical News - Discovery Labs Turns Focus To Surfaxin Market Strategy - October 20, 2012". Pharmacy Choice. Retrieved 2012-10-20.
↑ "List Of Orphan Products Designations And Approvals". Google2.fda.gov. Retrieved 2012-10-20.
↑ "Page expired". Nelm.nhs.uk. Retrieved 2012-10-20.
↑ Charatan, Fred (10 March 2001). "Surfactant trial in Latin American infants criticised". BMJ. 7286. 322: 575. doi:10.1136/bmj.322.7286.575/b. PMC 1119782. PMID 11238147.

[1] [1]^{[dead link]}

[2] "FDA approves Surfaxin to prevent breathing disorder in premature infants". Fda.gov. 2012-03-06. Retrieved 2012-10-20.

[POPG,_a_Key_Component_of_Discovery_Labs'_KL4_Surfactant,_Identified_as_a_Novel_Anti-Viral_Therapeutic_Approach-3] ttp://money.cnn.com/news/newsfeeds/articles/globenewswire/182115.htm. Missing or empty |title= (help) ^{[dead link]}

[Bronchopulmonary_segmental_lavage_with_Surfaxin_(KL(4)-surfactant)_for_acute_respiratory_distress_syndrome.-4] PMID 10508806 (PMID 10508806)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

[Lucinactant:_a_novel_synthetic_surfactant_for_the_treatment_of_respiratory_distress_syndrome.-5] 5.0 ^5.1 PMID 15833063 (PMID 15833063)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

[A_multicenter,_randomized,_controlled_trial_comparing_Surfaxin_(Lucinactant)_lavage_with_standard_care_for_treatment_of_meconium_aspiration_syndrome.-6] PMID 12042546 (PMID 12042546)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

[7] "Scripps Research Discoveries Lead to Newly Approved Drug for Infant Respiratory Distress Syndrome". Scripps.edu. 2012-03-06. Retrieved 2012-10-20.

[8] "Pharmaceutical News - Discovery Labs Turns Focus To Surfaxin Market Strategy - October 20, 2012". Pharmacy Choice. Retrieved 2012-10-20.

[9] "List Of Orphan Products Designations And Approvals". Google2.fda.gov. Retrieved 2012-10-20.

[10] "Page expired". Nelm.nhs.uk. Retrieved 2012-10-20.

[11] Charatan, Fred (10 March 2001). "Surfactant trial in Latin American infants criticised". BMJ. 7286. 322: 575. doi:10.1136/bmj.322.7286.575/b. PMC 1119782. PMID 11238147.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]